Literature DB >> 15189972

Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia.

Andre C Kalil, Susan E Puumala, Julie Stoner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189972     DOI: 10.1378/chest.125.6.2370

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  8 in total

Review 1.  Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.

Authors:  H Jiang; R-N Tang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-10       Impact factor: 3.267

3.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

4.  Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Allan J Walkey; Max R O'Donnell; Renda Soylemez Wiener
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

Review 5.  Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.

Authors:  Yan Wang; Yamin Zou; Jiao Xie; Taotao Wang; Xiaowei Zheng; Hairong He; Weihua Dong; Jianfeng Xing; Yalin Dong
Journal:  Eur J Clin Pharmacol       Date:  2014-10-30       Impact factor: 2.953

6.  Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Aisling R Caffrey; Brian J Quilliam; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 7.  Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Authors:  Matthew E Falagas; Konstantinos Z Vardakas
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis.

Authors:  Andre C Kalil; Michael Klompas; Gleb Haynatzki; Mark E Rupp
Journal:  BMJ Open       Date:  2013-10-14       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.